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Abstract. Although the high case fatality rate (CFR) associated with Ebola virus disease (EVD) is well documented,
there are limited data on the actual modes of death. We conducted a retrospective, observational cohort study among
patients with laboratory-confirmed EVD. The patients were all seen at the Eternal Love Winning Africa Ebola Treatment
Unit in Monrovia, Liberia, from June to August 2014. Our primary objective was to describe the modes of death of our
patients and to determine predictors of mortality. Data were available for 53 patients with laboratory-confirmed EVD, with
a median age of 35 years. The most frequent presenting symptoms were weakness (91%), fever (81%), and diarrhea
(78%). Visible hemorrhage was noted in 25%of the cases. The CFRwas 79%. Odds of death were higher in patients with
diarrhea (odds ratio = 26.1, P < 0.01). All patients with hemorrhagic signs died (P < 0.01). Among the 18 fatal cases for
which clinical information was available, three distinct modes of death were observed: sudden death after a moderate
disease process (44%), profuse hemorrhage (33%), and encephalopathy (22%). We found that these modes of death
varied by age (P = 0.04), maximum temperature (P = 0.43), heart rate on admission (P= 0.04), time to death from symptom
onset (P = 0.13), and duration of hospitalization (P = 0.04). Although further study is required, our findings provide a
foundation for developing treatment strategies that factor in patients with specific disease phenotypes (which often
require theuseof aggressive hydration). These findingsprovide insights into underlyingpathogenicmechanisms resulting
in severe EVD and suggest direction for future research and development of effective treatment options.
INTRODUCTION
The 2013–2016 West Africa Ebola virus disease (EVD) out-
break was unprecedented, given its duration, geographic
scope, and high caseload ofmore than 28,600 reported cases
and 11,300 deaths.1 In Monrovia, Liberia, faith-based orga-
nizations (Samaritan’s Purse and SIM) developed and oper-
ated the Eternal Love Winning Africa (ELWA-1 and 2) Ebola
Treatment Units (ETUs) from June to August 2014, with the
support of Medecins Sans Frontieres-Belgium (MSF-B).
During the period when the study was conducted, rapid
spread of EVD occurred because of high population density in
urban areas, unavailability of treatment units, and refusal of
many ill people to seek care because of fear and superstition.
In addition, fear prompted the surrounding community to arm
themselves with machetes and protest in front of ELWA-2,
demanding its closure in late July. This resulted in delays in
developing the ELWA-3 ETU, which was intended to provide
additional bed capacity. Limited knowledge of EVD led to
challenges in recognizing the disease on the part of health-
care workers, because of similarities in the presenting symp-
toms with endemic diseases such as malaria and typhoid
fever. As a result, patients often presented in the late stages of
EVD or died in the community without receiving appropriate
treatment. Although caseloads continued to climbwith limited
bedcapacity, the numberof actors operating in Liberia remained
extremely limited. ELWA-2 was the only functioning ETU in
Monrovia at the end of July 2014.
To date, there has been no description in the literature of the
predominant modes of death seen in the outbreak. Several
studies have reported the clinical features of EVD and pre-
dictors of mortality. Studies from Guinea established an as-
sociation between age, viremia, myalgia, hemorrhage,
difficulty breathing, and mortality.2–4 A study from Sierra
Leone emphasized that high viral load, severe hepatitis, and
acute kidney injury are also predictors of mortality.5 Resource
limitations, along with weak health systems in the affected
countries, have to some degree prevented the determination
of a comprehensive physiological mechanism of death. In-
stead, a descriptive approach to modes of death, defined as
clinical characteristics observed in a patient leading to (and
inclusive of) their terminal event, provides an opportunity to
further understand the pathogenesis of the disease and
guides areas for further research. In this article, we describe
three distinct modes of death witnessed in a subset of our
study population. A better understanding of predictors of
death and themodes of deathwill assist with the development
of improved clinical protocols and refine overall clinical care
for patients with EVD. We conducted a retrospective, obser-
vational cohort study of clinical manifestation, modes of
death, and predictors of mortality among confirmed cases of
EVD admitted to ELWA-1 and ELWA-2.
MATERIALS AND METHODS
The study protocol was approved by the Institutional Re-
view Board at the University of Liberia and the Liberian Min-
istry of Health.
Study site and patients. Patients were seen at the ELWA-1
and ELWA-2 ETUs on the outskirts of Monrovia, Liberia, from
June to August 2014. The ETU was run by faith-based
organizations—Samaritan’s Purse and SIM—in partnership
with the Liberia Ministry of Health and the nongovernmental
organization MSF-B. The period covered in the study was a
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verydifficult time inMonrovia,withpatient numbers andneeds
far outnumbering medical staff, beds, and resources. To ac-
commodate patients, the ELWA hospital chapel was trans-
formed into a five-bed facility called theELWA-1ETU.ELWA-1
was soon replaced by ELWA-2, a 14-bed facility. The Liberian
MOH had set up an ETU at John F Kennedy Hospital in
Monrovia, but all the patients were transferred to ELWA-2 on
its opening. ELWA-2 was the only functional ETU in Monrovia
at that time. In the 24 hours after the opening of ELWA-2, the
seven confirmed bed spaces were increased to 12, to ac-
commodate the rapidly increasing number of patients. Within
5 days, 20 bed spaces had to be made, which necessitated
significant reconfiguration of the ELWA hospital outpatient
department, including the removal of entire walls. The influx of
patients remainedunabated, andsoon, patientswere required
to lie on the floor to accommodate them. To make matters
worse, because of a lack of burial teams, the ELWA-2morgue
was often overflowing.
A major limitation in providing care was the severe scarcity
of trained staff, both national and international. A small group
of international staff worked alongside Liberian staff, often
working 12- to 14-hour shifts, 7 days in a row. Fear of con-
tractingEbola affected the recruitment of newstaff, whichwas
later exacerbated by infections among health-care workers at
ELWA-2. Because of the condition of many patients at ad-
mission, large volumes of intravenous fluids were required.
Because of the difficult circumstances mentioned earlier, it
was not possible to provide the necessary volumes for all the
patients, especially with the additional time constraints that
resulted from the necessity of complex personal protective
equipment.
All the patients included in the studywere confirmed to have
EVDby reverse transcription polymerase chain reaction (PCR)
performed at the Liberia Institute of Biomedical Research lab-
oratory outside of Monrovia.6 During this period, the laboratory
did not provide cycle threshold values to the ETU, and this
information is not traceable from the laboratory because of the
difficulties in linking sample data to patients from this stage of
the outbreak.
Data collection. Data were collected on exposure/
occupational history, county of residence, vital signs, clinical
signs and symptoms, PCR results, and outcomes for all pa-
tients admitted to the ETU (Tables 1 and 2). Patients were
assessed at triage by a physician or physician’s assistant,
then examined daily in the high-risk zone, where vital signs
(temperature, heart rate, and respiratory rate) and physical
examination findings were shared in real time with a scribe
located in the low-risk zone. Although assessments were
conducted for features of shock, such as capillary refill time
and quality of pulse, this information was not consistently
recorded and, therefore, cannot be interpreted from the data
set. Available resources at that time did not allow for clinical
laboratory testing, including monitoring of electrolytes.
Evaluation ofmode of death.Reporting themode of death
was done in situations where the patient’s clinical condition
had been consistently witnessed by the clinical team pre-
cedingdeath. In addition, it was included in the caseof sudden
deathwhen the patient had beenwitnessed to be stable, alert,
and mobile shortly before death, without signs of profuse
hemorrhage. As such limited records are available (N=18), the
mean characteristics of which are presented in Table 3. The
modes of death described were not determined in advance.
We describe three distinct modes of death, as directly wit-
nessed by the ELWA-2 clinical team leader. As staffing levels
at the ETU were inadequate, all modes of death evaluations
were made by a single observer. Postmortem examination
was not possible. The following modes of death were
observed:
1. Profuse hemorrhage
Occurring 5–7 days from symptom onset, death ensued
from a terminal hemorrhagic event within 24 to 48 hours of
onset of frank hemorrhage.
2. Encephalopathy
Commencing 7–8 days after symptom onset, a reduced
conscious level (responsive only to pain) developed, with a
marked pyrexia (> 39.4C) and tachypnea that progressed
to Kussmaul breathing, with rapid deterioration and death
within approximately 48 hours of reduced conscious level.
3. Sudden death
Sudden death is defined as a sudden, unexpected, and
immediate terminal event,whichwasnotovertly hemorrhagic
TABLE 1
Baseline and clinical characteristics of patients with confirmed Ebola
virus disease at ELWA-1 and ELWA-2
Characteristic Result
Median age, years (IQR) 35 (28.5–45)
Male:female ratio 28:25 (1.1:1)
Case fatality rate 79.2%
Median duration of hospitalization, days
(IQR)
5 (3–9)






Family member of health-care worker 5 (9%)
Funeral 4 (7%)
Church (hands-on praying of patients
by pastor)
1 (2%)
Assisted with patient transport 1 (2%)
Market contact 2 (4%)



















Visible hemorrhage 11/44 (25%)
Respiratory distress 9/44 (21%)
Hiccups 2/44 (5%)
Vital signs on admission (median/IQR)
Temperature (C) 37.2 (36.8–38.2)
Heart rate (beats per minute) 88 (80–102)




ELWA = eternal love winning Africa; IQR = interquartile range. N = 53.
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innature, followingamoderate illnessofapproximately10–12
days. In most cases, this terminal event presented as a
seizure-like event or sudden collapse in an ambulating
patient.
Treatment. All patients received treatment according to
standard MSF protocols, including oral rehydration solution,
intravenousantibiotics, antimalarial therapy, vitaminsAandC,
and analgesia and sedation when required. All patients with
poor oral intake or heavy fluid losses received intravenous
fluids. However, because of limitations in accessing patient
charts, the volumes administered cannot be reliably reported.
Variables. We evaluated mortality among patients with
EVD as a binary variable—death in the ETU or survival. In-
dependent variables evaluated included the following binary
TABLE 2
Characteristics of survivors and nonsurvivors
Characteristic Survivors N = 11 Nonsurvivors N = 42 Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Median age (IQR) 40 (23–43) 35 (29.8–48.2) – 0.63 – –
Male:female ratio 1.8:1 1.9:1 1.1 (0.2–5.3) 1 1.0 (0.2–4.8) 1
Health-care worker 4/11 (36.4%) 14/41 (34.1%) 0.9 (0.2–5.0) 1 1.0 (0.2–6.2) 1
Median duration of hospitalization in days
(IQR)
17 (13.5–20.5) 4 (2.3–6) – 3 × 10−6 – –
Duration of hospitalization > 10 days* 9/11 (81.8%) 1/42 (2.4%) 136 (12–7,650) 1 × 10−7 124 (10.6–7,380) 2 × 10−7
Median days (IQR) between symptom
onset and admission
4.5 (2.3–6.8)) 5 (3–7) – 0.67 – –
Signs and symptoms
Weakness 8/9 (88.9%) 32/35 (91.4%) 1.3 (0.0–19.3) 1 1.0 (0.0–16) 1
Fever 8/11 (72.7%) 31/37 (83.7%) 1.9 (0.3–11.6) 0.41 1.8 (0.2–10.5) 0.67
Diarrhea 2/9 (22.2%) 33/36 (91.7%) 32.8 (4.1–464) 8 × 10−5 26.1 (3.5–332) 2 × 10−4
Nausea 6/9 (66.7%) 26/36 (72.2) 1.3 (0.2–7.6) 0.7 1.3 (0.2–7.8) 0.7
Vomiting 4/9 (44.4%) 23/36 (63.9%) 2.2 (0.4–13.1) 0.45 2.1 (0.4–12.7) 0.45
Abdominal pain 4/9 (44.4%) 18/32 (56.2%) 1.6 (0.3–9.6) 0.71 1.42 (0.2–8.8) 0.72
Headache 3/8 (37.5%) 18/32 (56.2%) 2.1 (0.3–15.9) 0.44 2.4 (0.4–17.7) 0.43
Hemorrhagic symptoms:
Visible† 0/10 (0%) 11/34 (32.4%) ‡ 0.046 ‡ 0.041
Subconjunctival† 0/10 (0%) 13/34 (38.2%) ‡ 0.021 ‡ 0.019
Combined 0/10 (0%) 17/34 (50.0%) ‡ 3.7 × 10−3 ‡ 2.9 × 10−3
Respiratory distress 2/10 (20%) 7/34 (20.6%) 1.0 (0.2–12.2) 1 1.1 (0.2–12.8) 1
Hiccups 0/10 (0%) 2/34 (5.9%) ‡ 1 ‡ 1
Vital signs
Median temperature (C) on admission
(IQR)
38 (37–38.6) 37.2 (36.8–37.9) – 0.26 – –
Median maximum temperature (C)
during admission (IQR)
38.4 (38–39.2) 38.6 (38–39.4) – 0.81 – –
Median admission heart rate (IQR)
(beats per minute)
77 (70–84) 88 (82–102) – 0.1 – –
Medianadmission respiratory rate (IQR)
(breaths per minute)
27 (25–30) 22 (20–27) – 0.23 – –
CI = confidence interval; IQR = interquartile range; OR = odds ratio.
* 10 days is the midpoint in the median duration of hospitalization between those who died and those who survived.
†Visible hemorrhagic symptoms refer to active bleeding from one or more sites; subconjunctival refers to the severe conjunctivitis several patients presented with, some of whom progressed to
frank subconjunctival hemorrhage.
‡All patients with these symptoms died, resulting in an infinite OR.
TABLE 3
Characteristics of modes of death
Characteristic
Mode of death
Hemorrhagic Encephalopathy Sudden death
Time todeath fromsymptomonset (days):
median IQR)
8 (7.25–9.25) 10 (9.5–11) 12 (9.5–13.5)
P value* 0.13 1 0.17
Age (years): median (IQR) 27 (26–30) 47 (37.3–57) 33 (31.5–45)
P value* 0.045 0.041 0.92
Maximum temperature (C): median (IQR) 38.6 (37.8–38.8) 39.1 (38.1–40.1) 38.6 (38.1–39.4)
P value* 0.67 0.43 0.77
Admission heart rate (beats per minute):
median (IQR)
84 (80–104) 100 (94–108) 85 (83–88)
P value* 0.65 0.067† 0.24
Onset of symptoms to hospitalization
(days): median (IQR)
4 (3.75–4.75) 6 (5–6.5) 5 (4–6.5)
P value* 0.42 0.47 0.90
Durationofhospitalization (days):median (IQR) 4 (4–5) 4.5 (3.75–5) 8.5 (5.5–9.25)
P value* 0.22 0.27 0.041
IQR = interquartile range.
*P value for the comparison of the individual mode of death vs. the other two modes of death combined.
†When an individual comparison is made between the encephalopathy mode of death and sudden death, the P value for admission heart rate falls to 0.045.
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variables: gender and presence or absence of symptoms (on
admission and daily). The following continuous variables were
evaluated: time at onset of symptoms to admission, duration
of hospitalization, and vital signs on admission.
Statistical analysis. Mode of death and patient character-
isticswere summarized usingdescriptive statistics.P values for
differences of binary characteristics between survivors and
nonsurvivors were calculated using Fisher’s exact test, and
unadjusted odds ratios (ORs) for the effect of the characteristic
on mortality were calculated directly from 2 × 2 contingency
tables.ORs andP values adjusted for ageolder thanor younger
than 40 years were calculated using the Cochran–Mantel–
Haenszel exact test. P values for differences in continuous
characteristics between modes of death and survivors and
nonsurvivors were calculated using the nonparametric Kruskal–
Wallis test. For continuous covariates, ORs were only re-
ported for those that were statistically significant; in our
analyses, this was found to be duration of hospitalization.
The OR was calculated for binary characteristics by defining
a binary covariate, setting the duration of hospitalization at a
threshold, calculated as the midpoint between the medians
in survivors and nonsurvivors. The Breslow–Day test was
used to identify differential effects of age older than or
younger than 40 years. Hypothesis testswere two tailed, with
a P value of less than 0.05 indicating statistical significance.
All statistical analyseswere performedwith ‘R’ Language and
Environment for Statistical Computing (R) 3.2.2.
RESULTS
Baseline characteristics. Of the 69 patients admitted to
the ELWA-1 and ELWA-2 ETUs from June to August 2014, 53
(77%) were confirmed EVD cases. Of the remainder, five had
no determinable result, threewere not tested, and eight tested
negative for EVD. The three who were not tested were either
deceased on arrival or died within a few hours of admission.
Table 1 describes the basic patient characteristics and
symptom incidence. A comparison of characteristics of pa-
tientswho survived versus thosewhodied is shown in Table 2.
Denominator figures may vary because of missing data.
The majority of EVD-positive patients admitted to ELWA
from June to August 2014 resided in Montserrado County,
although patients were also admitted from Bomi, Bong, Mar-
gibi, and Grand Bassa counties (Figure 1). The primary mode
of transmission was nosocomial, with 28% of patients
reporting nosocomial transmission, followedby direct contact
with a household member (26%).
The median age of patients was found to be 35 years
(Interquartile range [IQR] = 28.5–45); the median age among
nonsurvivors was lower (35 years, IQR = 29.8–48.2) than that
among survivors (40 years, IQR = 23–43) but was not
FIGURE 1. Map of county of residence of confirmed Ebola virus disease (EVD) cases. This figure appears in color at www.ajtmh.org.
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statistically significant (P = 0.63). The case fatality rate (CFR)
was 79% among all patients (Table 1).
The most common symptom was weakness (91%), fol-
lowed by fever (81%) and diarrhea (78%). In comparison with
other data sets, our patients had a relatively high incidence of
hemorrhagic signs at 38.6%. An absence of fever was noted
among 18.8% of all laboratory-confirmed Ebola patients on
admission (Table 1). Although the temperature range on ad-
mission was broad (35.6– 39.2C), only one patient presented
with clinical hypothermia; this patient died within a few hours
of admission.
Modes of death. When analyzed, the modes of death de-
scribed previously revealed differences in the age of the pa-
tients, the maximum temperature, the time to death from
symptomonset, and the heart rate on admission (Table 3). The
median time to death values were not statistically significant,
but orientation of values is demonstrated in Figure 2. For
profuse hemorrhage, themedian time to death was 8 days; for
encephalopathy, it was 10 days; and for sudden death, it was
12 days. Figure 3 demonstrates that the variation in time to
death is predominantly due to the patient’s duration of hos-
pitalization as opposed to the length of time between onset of
symptoms and admission to the ETU.
Patients who died of profuse hemorrhage were generally
younger (Figure 4), with a median age of 27 years (IQR =
26–30), which was significantly different (P = 0.045) from the
other twomodes of death combined: encephalopathymedian
age of 47 years (IQR = 37.3–57) and sudden deathmedian age
of 33 years (IQR=31.5–45). Themedian age of 47 years for the
encephalopathy mode of death was also significantly higher
than that of the other two modes of death combined (P =
0.041). The distribution of age by mode of death is shown in
Figure 4.
Those in the hemorrhagic category had a tendency to have
a lower Tmax (median 38.6C, IQR = 37.8–38.8) than those in
the other categories but demonstrated the same median
temperature as those in the sudden death category (38.6C,
IQR=38.1–39.4). Thosewith encephalopathy demonstrated a
higher Tmax (median 39.1C, IQR = 38.1–40.1); this mode of
death had clinical features that could be consistent with a
cytokine storm. These differences were not statistically sig-
nificant, but the ranges are demonstrated in Figure 5. Of note,
themedianheart rate onadmissionwassignificantly lower (P=
0.045) for the sudden death category (85 beats per minute,
IQR = 83–88) when compared with that in the encephalopathy
mode of death (100 beats per minute, IQR = 94–108) as
demonstrated in Figure 6.
When compared with survivors, there was unsurprisingly a
significant difference betweenmodes of death and duration of
hospitalization (P < 0.01 for all modes of death), as demon-
strated in the comparison of survivors and deceased patients
shown in Table 2. The only other variable that significantly
differed from survivors (P = 0.043) was between the median
admission heart rate in the encephalopathy mode of death
(100 beats per minute, IQR = 94–108) and the median ad-
mission heart rate of survivors (77 beats per minute, IQR =
70–84).
Associationbetweendiarrhea,hemorrhage,andmortality.
Patientswith diarrhea had higher odds of death (OR= 26.1, 95%
confidence interval = 3.5–332, P < 0.01) compared with those
without diarrhea. All patients who exhibited any type of hem-
orrhagic symptom died, although the terminal event for a pro-
portion of these patients was not profuse hemorrhage; some
had a more moderate disease process terminating in a sudden
death event that was not overtly hemorrhagic. Other patients
demonstratedovert hemorrhagic symptoms thatprogressed to
a profuse and ultimately terminal hemorrhagic event (profuse
hemorrhagemodeofdeath).Where recordsareavailable, those
patients with mild hemorrhagic symptoms demonstrated a
moderate disease process which terminated with a sudden
death event (sudden death mode of death). Patients in the
FIGURE 2. Time to death fromsymptomonset comparedwithmode
of death in Ebola virus disease. This figure appears in color at www.
ajtmh.org.
FIGURE 3. Duration of hospitalization by mode of death. This figure
appears in color at www.ajtmh.org.
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encephalopathy mode of death demonstrated hemorrhagic
conjunctivitis but did not demonstrate signs of overt bleeding.
Treatment. Comprehensive data on the volume of in-
travenous fluids that patients received are not available.
Documentation of whether fluid administration was given is
available for 33 patients. Of these 33 patients, 30 (91%) re-
ceived intravenous fluids. Of the threewho did not, one died at
triage before obtaining intravenous access, one declined in-
travenous fluids (this patient went on to survive), and the third
patient demonstrated minimal symptoms for only 24 hours,
despite a contact history and positive EVD PCR; this patient
also survived.
DISCUSSION
A stark finding from this small data set is the well-defined
modes of death and clinical syndrome patients demon-
strated in the 24 to 48 hours before death and the suggestion
that these differed with age and duration of hospitalization,
but not time from symptom onset to presentation at a treat-
ment facility. There could be several reasons for this in-
cluding a slightly different underlying pathogenesis or
interaction between the immune system and virus at different
ages. Genetic predisposition dictating immune response
may be another possible explanation for the varied modes of
death observed and is currently under investigation. Given
the evidence for minimal viral sequence variation during the
epidemic, varied pathogenicity of the infecting virus is
unlikely.7,8
Modes of death. The modes of death described suggest
potential mechanisms of pathogenesis leading to death. This
may indicate that earlier clinical interventions might be
appropriate in the management of cases, such as early iden-
tification and aggressive management of coagulopathy. Al-
though these categories are not documented elsewhere in the
literature, written correspondence with colleagues present
during the early stages of the epidemic in all three heavily
affected nations highlighted similar categories. This should be
studied in more detail as understanding these mechanisms
may help to further prioritize treatment of those likely to de-
teriorate more rapidly.
The sudden death category is of particular interest as these
patients suffered a longer and more moderate illness when
compared with the other two categories, with a significantly
longer hospital admission (P = 0.041), but no difference in the
time to admission from symptom onset (P = 0.90). These pa-
tients often appeared as if they may survive yet experienced a
sudden event that resulted in death. Although some suffered a
terminal seizure event, the cause of this remains unclear. This
may have been from direct viral invasion of neural tissue or the
consequence of intracranial hemorrhage, vaso-occlusive events,
electrolyte disturbances, or cardiac arrhythmias. Those pa-
tients who did not suffer a witnessed seizure event were
simply found collapsed, usually while ambulating. It is un-
clear if a seizure had occurred. This group of patients did not
display clear symptoms of encephalitis, but some demon-
strated a mild hemorrhagic tendency such as bleeding
around IV line sites. Interestingly,many of thosewhodied of a
sudden death event were found to be in full rigor mortis when
death was being certified, which was often within an hour of
death, if not less than 30 minutes of death.
All patients who died of profuse hemorrhage had frank
hemorrhagic signs in the 24 to 48 hours before death, often
from multiple locations, which gradually became more pro-
nounced in the lead up to a final profuse hemorrhagic event.
Many patients who went on to have a terminal hemorrhagic
event were noted to become afebrile approximately 24 to
48 hours before the onset of frank hemorrhagic signs. This
may reflect defervescencebefore aprofusehemorrhagic event.
A similar period of defervescence has been noted in dengue
shock syndrome shortly before the onset of shock9–11 and
may reflect decompensated shock in patients with EVD also.
Some patients had mild hemorrhagic signs, such as
bleeding around intravenous line sites, melena, or metror-
rhagia. However, their death did not result from an obvious
profuse, terminal hemorrhagic event. The majority of these
patients presented a picture consistent with sudden death, as
their disease processwasmoderate andmore prolonged, and
their terminal event was a collapse or a seizure-like event. It
cannot be determined whether they suffered a sudden in-
tracranial hemorrhagic event, but this must be given due
FIGURE 5. Maximum temperature distribution by mode of death in
Ebola virus disease. This figure appears in color at www.ajtmh.org.
FIGURE 4. Relationship of age to mode of death in Ebola virus dis-
ease. This figure appears in color at www.ajtmh.org.
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consideration. The patients in the encephalopathy category
were not noted to have any overt hemorrhagic symptoms
other than conjunctivitis.
The patients in the encephalopathy mode of death presented
withclinical featuressimilar toacytokinestormwithhyperpyrexia,
encephalopathy, and featuresofacidosissuchas tachypneawith
Kussmaul breathing. It is interesting that these patients seemed
tobe inanolderagecategory (Figure4) andweremore likely tobe
tachycardic at admission (Figure 6) when compared with other
modesofdeathandwithsurvivors. Itmaybe that theyhadamore
profound cytokine production in response to infection than other
modes of death, whichmay explain amore rapid deterioration to
shock and then death. However, diffuse proinflammatory cyto-
kine production may also be related to the frank hemorrhage12
noted in the hemorrhagic mode of death.
Predictors of mortality. In the analysis of clinical symp-
toms and outcomes, diarrhea was a significant predictor of
death (OR = 26.1,P < 0.01). These findings are similar to those
of other studies that have suggested that intravascular volume
depletion likely leads to worse outcomes among patients with
EVD.3–5,13 For this reason, interventions such as aggressive
oral and intravenous rehydration are recommended in the
early stages of disease for patients with EVD.3–5,13 Although
approximately 90% of our patients received intravenous fluid,
itwasnot possible to reliably assess the impact of this from the
current data set. Although some patients may have received
adequate fluid resuscitation, some patients with EVD require
in excess of 10 L of intravenous fluids per day to meet their
ongoing losses.13,14 It was not possible to administer this level
of fluid resuscitation because of the extreme staffing con-
straints, number of patients, and lack of available beds.
We reported hemorrhagic signs in 38.6% of our patients,
which is similar to a study from Guinea but higher than what
hasbeen reportedelsewhere.4,5,15Ascertainingwhetherpatients
had melena can be difficult, which may account for the lower
rates of hemorrhagic disease reported in other study cohorts. It
may also be that milder cases of EVD did not present to the ETU
for treatment, given thecircumstancesat the time, resulting in the
population of this study being more representative of those with
severe disease.
Triage processes that distinguish severity of illness should
take into account the presence of either diarrhea or hemor-
rhage on admission, given the higher likelihood of death and
greater needs with regard to clinical and hygiene manage-
ment. Similar to a study in Sierra Leone, we found that a
moderate proportion of patients with confirmed EVD pre-
sented without a fever at the time of admission.16 This finding
has repercussions regarding screening and triage protocols,
which may need to be reevaluated.
In April 2015, theWorld Health Organization reported CFRs
in Liberia to be 42%, a significant decline from CFRs at ELWA
in June to August estimated at 79% (Table 1). CFRs at the
onset of the outbreak in Liberia in June to August were higher
than those in neighboring Guinea (60%) but consistent with
CFRs previously reported for EBOV outbreaks.17–19 A recent
study in Cell found that an Ebola glycoprotein mutant (GP-
A82V) arising early during the West African epidemic in-
creased infectivity of humancells andmayhave contributed to
increasedmortality in Liberia and Sierra Leone. The authors of
this study found that both viral load and GP-A82V were sig-
nificantly associated with increasedmortality.20 Thismutation
may have led to increased viremia among cases in Monrovia,
which has been shown to account for increased CFRs.2
In our study cohort, the fatal cases had amedian number of
hospitalization days of 4, and 52%died within 4 days of being
admitted. Although there was no significant association be-
tween the interval of symptom onset and ETU admission and
mortality, this is contrary to a study in Sierra Leonewhere such
an association was found.16 Our study was likely underpow-
ered to find such an association. The decline in the CFR as the
epidemic evolved was likely due to multiple factors including
a decrease in the time between symptom onset and hospi-
talization. This may have resulted in lower viremia at the time
of admission. Previous studies suggest that lower viremias at
the time of admission are associated with more favorable
outcomes.2,5 Improved training of health-care workers and
better staff-to-patient ratios in treatment facilities likely also
contributed.
Limitations. Our study had several limitations. The small
sample size will have affected the power to determine signif-
icant differences and associations. Because of limitations in
laboratory diagnostics and imaging, it was not possible to
determine the exact mechanism of death, only to conduct
careful observations of the mode. As the mode of death was
noted by a single observer, this introduces an observer bias
but doesavoid interobserver variability. In the future, access to
basic biochemistry and acid–base balance data on patients
would help to determine, or at least exclude, certain mecha-
nisms of death. More detailed laboratory diagnostics would
have also provided further insights into the association be-
tween factors such as anemia, thrombocytopenia, electrolyte
deficiencies, renal failure, transaminitis, acidosis, coagulop-
athy, and outcomes.
In conclusion, we describe three distinct modes of death
that patients with EVD succumbed to. This highlights the
need for better understanding of the mechanisms of death in
EVD to provide further insights into the pathogenesis and
complications of the disease. We also demonstrate a strong
association between diarrhea, hemorrhage, and mortality,
suggesting that more aggressive hydration and a higher level
FIGURE 6. Admission heart rate distribution by mode of death in
Ebola virus disease. This figure appears in color at www.ajtmh.org.
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of care for patients presenting with diarrhea or hemorrhage
may improve outcomes.
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